[A randomized controlled trial of immunochemotherapy using carmofur (HCFU), mitomycin C and immunopotentiators in advanced gastric cancer following noncurative resection and nonresection].
The cumulative survival rate of 166 gastric cancer patients after noncurative resection and nonresection treated by combination therapy using carmofur (HCFU), mitomycin C (MMC) and immunopotentiators was investigated. A randomized controlled trial composed of MMC and immunopotentiators (group A) versus the addition of HCFU to group A (group B) was undertaken. In all patients, the survival curve of group B was superior to that of group A (g. Wilcoxon test, p = 0.078). Noncurative resection or nonresection patients presented significantly higher survival rates in group B (p less than 0.05) after analysis according to the duration of the treatment period (Z-test). Stratification of backgrounds for noncurative patients also showed significantly higher survival rates in group B (p less than 0.05) at S 3, P, stage IV. From these results, it might be suggested that HCFU therapy is useful for gastric cancer patients after noncurative resection and nonresection.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000276:Adjuvants, Immunologic; D008937:Mitomycins; D016685:Mitomycin; C017367:carmofur; D005472:Fluorouracil